Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imitrex "Authorized" Generic Launch Planned In Q4 2008

This article was originally published in The Pink Sheet Daily

Executive Summary

GlaxoSmithKline and Dr. Reddy's reach settlement agreement on the migraine tablets allowing a generic launch several months prior to patent expiration.

You may also be interested in...



Dr Reddy’s Launches Generic Versions Of GSK’s Imitrex; Ranbaxy May Have To Wait

MUMBAI - One more blockbuster drug will be available to U.S. citizens at a fraction of its brand price as India's Dr Reddy's announced the launch of generic versions of GlaxoSmithKline's anti-migraine drug Imitrex (sumatriptan)

Latest Imitrex Patent Settlement Protects GSK’s “Authorized” Generic

Dr. Reddy’s sumatriptan generic will likely hit the market several months before Cobalt’s launches in 2009.

Latest Imitrex Patent Settlement Protects GSK’s “Authorized” Generic

Dr. Reddy’s sumatriptan generic will likely hit the market several months before Cobalt’s launches in 2009.

Related Content

Topics

UsernamePublicRestriction

Register

ID1132679

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel